3 Biotech Stocks Holding Down The Debt And On Track For Growth

For a biotechnology company to become successful, it requires a significant amount of coordination between research, development, creativity, expertise and persistence. It can be a long road to get products to market. So it is understandable that many biotech companies utilize debt to finance those before-market years. However, it also sets these companies up on a slower track for growth. For our scan today, we sought out biotech companies that have managed to build a solid portfolio of interventions and treatments without taking on excessive debt. The idea is that by remaining relatively debt free, these companies can focus on growth. Further, these companies have significant projected EPS growth rates for the next five years. The summaries and graphs below are a helpful place for you to start your own assessment of these biotech stocks.EPS growth (earnings per share growth) illustrates the growth of earnings per share over time.
... Read the rest at SeekingAlpha.com